EX9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And ProfitabilityExceptional operating and free cash flow provide internal funding for clinical development, commercial investment and shareholder returns. The close conversion of earnings into cash also supports earnings quality, while high profitability gives Exelixis resilience and flexibility over the next several quarters.
Leading Commercial FranchiseGrowing prescription volume and market share indicate durable demand for CABOMETYX and reinforce its leading positions in RCC and second-line-plus NET. This commercial strength supports recurring product revenue and provides a platform for funding Exelixis’ broader oncology pipeline.
Patent-protected Market ExclusivityThe patent ruling extends protection for the company’s principal commercial product and reduces the near-term risk of generic erosion in the U.S. Preserving exclusivity supports revenue durability, cash generation and continued investment while separate litigation remains unresolved.
Bears Say
Lower 2026 Revenue GuidanceThe guidance reduction signals that near-term commercial growth is less predictable than previously expected. A slower NET contribution may constrain revenue expansion over the next several quarters and raises the execution burden on the existing cabo franchise and upcoming pipeline launches.
Higher Gross-to-net DeductionsHigher gross-to-net deductions reduce the revenue retained from branded product demand and can pressure realized growth even when prescription trends remain favorable. If the revised level persists, it may weigh on commercial margins and reduce the cash generated per unit sold.
Clinical And Regulatory UncertaintyUncertainty around clinical subgroup interpretation, regulatory pathways and market adoption could affect approval timing, labeling and uptake for future indications. These issues make pipeline contribution less certain and could limit the pace at which zanzalintinib becomes a new franchise.
Exelixis News
EX9 FAQ
What was Exelixis’s price range in the past 12 months?
Currently, no data Available
What is Exelixis’s market cap?
Exelixis’s market cap is CHF11.76B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s upcoming earnings report date is Nov 03, 2026 which is in 53 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Aug 05, 2026. The company reported CHF0.732 earnings per share for the quarter, beating the consensus estimate of CHF0.686 by CHF0.046.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Undervalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 0.71.
How many shares outstanding does Exelixis have?
Currently, no data Available
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of CHF0.732 in its last earnings report, beating expectations of CHF0.686. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Exelixis?
Currently, no hedge funds are holding shares in CH:EX9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Exelixis Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF42.08 (― Upside)
CHF42.08 (― Upside)
Blogger Sentiment
Bullish
CH:EX9 Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
52.33%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Exelixis
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
EX9 Company Deck
EX9 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects strong commercial performance, healthy profitability and a well-advanced zanzalintinib development program with multiple pivotal trials and a pending NDA/PDUFA. These positive fundamentals are tempered by a modestly slower-than-expected NET ramp that prompted a $50 million downward adjustment to revenue guidance, higher gross-to-net expectations (30%–31%), and some clinical/regulatory uncertainties (STELLAR-303 subgroup result, 505(b)(2) dynamics). On balance, the company’s execution, cash position (~$1.4B), active share repurchases, and deep pipeline milestones outweigh the near-term headwinds, supporting a constructive outlook while acknowledging short-term risks.View all CH:EX9 earnings summariesEX9 Revenue Breakdown
89.92% U.S.
7.92% Europe
2.16% Japan
